|| List of recent Polypeptide-related patents
|Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polynucleotides and polypeptides in plants|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
|Compositions and methods for altering alpha- and beta-tocotrienol content|
Preparation and use of isolated nucleic acids useful in altering the oil phenotype in plants. Isolated nucleic acids and their encoded polypeptides that alter alpha- and beta-tocotrienol content in seeds and oil obtained from the seeds.
|Polynucleotides and polypeptides that confer increased yield, size or biomass|
The present description relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant, including the traits of increased yield, size or biomass.. .
|Modified polynucleotides for treating carboxypeptidase n, polypeptide 1 protein deficiency|
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .
|Wnt compositions and methods of use thereof|
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”.
|Immunotherapeutic methods using epitopes of wt-1 and gata-1|
A peptide comprising the amino acid sequence rmfpnapyl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence cmtwnqmnl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence hlmpfpgpll or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines..
A method for releasing the content of the periplasmic space of bacterial cells is provided, which comprises incubating the bacterial cells in a solution containing styrene maleic acid copolymer (sma). Also provided is a method of preparing a substantially pure sample of recombinant polypeptide.
|Glucanases, nucleic acids encoding them and methods for making and using them|
The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-d-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-d-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-d-glucans or xyloglucans and other plant material containing cellulosic parts.
|Influenza b viruses having alterations in the hemaglutinin polypeptide|
The present invention encompasses methods of producing influenza b viruses in cell culture. The influenza b viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza b virus infection..
|Novel polypeptides and use thereof|
The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of seq id no: 1, the invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same..
|Stabilizing polypeptides which have been exposed to urea|
Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. .
|Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne|
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
|Process for the production of fine chemicals|
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use..
|Compositions comprising agents that inhibit neuropilin and tolloid like 2|
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. .
The present inventors produced a heterodimerized polypeptide having an fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an fc region with improved fc region function compared to that of a homodimer in which the fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.. .
|Structural mutations in titin cause dilated cardiomyopathy|
Provided herein are diagnostic markers and methods for identifying a subject having an increased susceptibility for developing or having dilated cardiomyopathy. The method comprises determining if the subject has a mutation in the ttn nucleic as acid or titin polypeptide.
|Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof|
Provided are soluble neutral active hyaluronidase glycoproteins (shasegp's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
|Axmi221z, axmi222z, axmi223z, axmi224z and axmi225z delta-endotoxin genes and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
|Plants having altered agronomic characteristics under nitrogen limiting conditions and related constructs and methods involving genes encoding lnt6 polypeptides and homologs thereof|
Isolated polynucleotides and polypeptides and recombinant dna constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an lnt6 polypeptide or homolog thereof..
|Plant transcriptional regulators|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
|B7-related nucleic acids and polypeptides useful for immunomodulation|
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
|Modified chimeric polypeptides with improved pharmacokinetic properties|
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
|Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use|
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight.
|Sequence-specific inhibition of small rna function|
The present invention relates to the discovery of a method for inhibiting rna silencing in a target sequence-specific manner. Rna silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide.
|Use of endostatin peptides for the treatment of fibrosis|
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed.
|Modified relaxin polypeptides and their uses|
Modified relaxin polypeptides and their uses thereof are provided. .
|Isolated nucleic acid molecules encoding variant activin receptor polypeptides|
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity|
The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to lactoferrin and pak fusion peptides (pak-lf), along with therapeutic, diagnostic and research uses for these polypeptides.
|Dfpase enzymes from aplysia californica|
The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Thermus brockianus nucleic acid polymerases|
The invention provides nucleic acids and polypeptides for nucleic acid polymerases from a thermophilic organism, thermus brockianus. The invention also provides methods for using these nucleic acids and polypeptides..
|Influenza virus immunogenic compositions and uses thereof|
Immunogenic compositions comprise a rna component and a polypeptide component. The rna component is a self-replicating rna.
|Peptide carrier fusion proteins as allergy vaccines|
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the n- and c-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.. .
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
|Soluble proteins for use as therapeutics|
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
|Drug fusions and conjugates|
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and glp and/or exendin molecules.
|Nicotiana nucleic acid molecules and uses thereof|
The present invention features nicotiana nucleic acid sequences such as sequences encoding constitutive, or ethylene or senescence induced polypeptides, in particular cytochrome p450 enzymes, in nicotiana plants and methods for using these nucleic acid sequences and plants to alter desirable traits, for example by using breeding protocols.. .
|Plants having enhanced yield-related traits and a method for making the same|
The present invention relates generally to the field of molecular biology and concerns a method for improving various plant yield-related traits and growth characteristics by modulating expression in a plant of a nucleic acid encoding a peamt (phosphoethanolamine n-methyltransferase) polypeptide, a fatty acyl-acyl carrier protein (acp) thioesterase b (fatb) polypeptide, or a lfy-like (leafy-like) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding a peamt polypeptide, a fatb polypeptide, or a lfy-like polypeptide, which plants have improved yield-related traits and growth characteristics relative to a corresponding wild type plant or other control plant.
|Methods and compositions|
Wherein said connector compound is attached to the polypeptide by at least three discrete covalent bonds. The invention also relates to libraries, and to methods for making complexes and to methods of screening using same..
|Methods for selecting protease resistant polypeptides|
The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity.
|Discordant helix stabilization for prevention of amyloid formation|
The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the α-helix of a discordant helix-containing polypeptide.
The invention is directed to a ca2+ precipatable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising ca2+ precipatable tags and cassettes..
|Method of modulating integrin mediated cellular activity and agents useful for same|
An isolated nucleic acid encodes a polypeptide for inhibiting growth of a cancer cell. The amino acid sequence defines a binding domain of a β integrin subunit for erk2 map kinase, the binding domain comprising an intervening, centrally located amino acid linker sequence that links opposite terminal end amino acid sequence regions of the binding domain together and is non-essential for binding of the map kinase to the binding domain.
|Peptide linkers for polypeptide compositions and methods for using same|
Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders)..
|Relaxin fusion polypeptides and uses thereof|
The present invention provides relaxin fusion polypeptides a-l-b with a non-wild type array of the relaxin a-chain and relaxin b-chain, wherein the a- and b-chains are connected by a linker peptide. The invention further provides relaxin fusion polypeptides with extended half-life.
|Methods for maintaining pegylation of polypeptides|
Described herein are methods for maintaining pegylation and inhibiting depegylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.. .
|Novel receptor nucleic acids and polypeptides|
Disclosed are nucleic acids encoding baff-r polypeptides, as well as antibodies to baff-r polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided..
|Methods and compositions for the diagnosis and treatment of epithelial cancers|
Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient ep-icd polypeptides and ep-icd polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear ep-icd polypeptides and optionally epex polypeptides are provided.
|Engineered tal effector proteins with enhanced dna targeting capacity|
The present invention provides compositions and methods for dna targeting using tal effectors and tal effector based proteins, including but not limited to targeted gene regulation and targeted cleavage of cellular chromatin in a region of interest and/or homologous recombination at a predetermined site in cells. Compositions include fusion polypeptides comprising a tal effector or a tal effector binding domain in combination with other domains, including but not limited to a cleavage domain.
|Selection of host cells expressing protein at high levels|
Provided is a dna molecule comprising a multicistronic transcription unit coding for i) a selectable marker polypeptide functional in a eukaryotic host cell, and for ii) a polypeptide of interest, the polypeptide of interest having a translation initiation sequence separate from that of the selectable marker polypeptide, wherein the coding sequence for the polypeptide of interest is downstream from the coding sequence for the selectable marker in the multicistronic transcription unit, and the nucleic acid sequence coding for the selectable marker polypeptide comprises a mutation that decreases the translation efficiency of the selectable marker in a eukaryotic host cell. Also provided are methods for obtaining host cells expressing a polypeptide of interest, the host cells comprising the described dna molecules.
|Method for identifying a malodor inhibitor|
Provided is a method for identifying a malodor inhibitor based on a response of an olfactory receptor. The present invention provides a method for identifying a malodor inhibitor including: adding a test substance and a malodor-causing substance to at least one olfactory receptor selected from the group consisting of or5p3, or5k1, or2w1, or8h1, and a polypeptide which has 80% or more identity in amino acid sequence to any one of the aforementioned polypeptides; measuring the response of the olfactory receptor to the malodor-causing substance; identifying the test substance which can suppress the response of the olfactory receptor based on the measured response; and selecting, as a malodor inhibitor, the test substance which can suppress the response of the olfactory receptor..
The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders..
|Composition having improved head stability and use thereof|
The object is to provide a composition effective for improving foam stability of a beer-based sparkling beverage and the like. Provided is a composition containing a protein or a polypeptide produced by using a protease and a transglutaminase to treat a protein material as an active component..
|Novel simian t-cell lymphotropic virus|
Disclosed are the simian t-cell lymphotropic virus type 3 subtype d (stlv-3 subtype d), isolated nucleic acid molecules encoding stlv-3 subtype d polypeptides, such as stlv-3 subtype d envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting stlv-3 subtype d, for example by detecting a stlv-3 subtype d nucleic acid or polypeptide in the sample.
|Immunotherapy with binding agents|
Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
|Pharmaceutical composition for treatment and/or prophylaxis of cancer|
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial caprin-1 polypeptide consisting of the amino acid sequence shown by seq id no: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer comprising the same as an active ingredient..
|Genetic products differentially expressed in tumors and the use thereof|
The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins..
|Surface, anchored fc-bait antibody display system|
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell.
|Coagulation factor ix compositions and methods of making and using same|
The present invention relates to compositions comprising factor ix coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.. .
|Modified acid alpha glucosidase with accelerated processing|
A modified human acid alpha-glucosidase polypeptide is provided, as well as methods of making and using modified human acid alpha-glucosidase to treat glycogen storage disorders.. .
|Compositions for directing adipose-derived stem cells to a chondrogenic differentiation and methods of use therefor|
Composition and methods are provided to stimulate the proliferation and differentiation of pluripotent stem cells into chondrocytes. The method comprises the steps of contacting the pluripotent stem cells with an ab2 chimeric polypeptide under conditions suitable for grown and proliferation of the cells..
|Reoviruses having modified sequences|
The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses..
|Polysaccharide and/or polypeptide based graft polymers as synthetic tannins|
A graft polymer of polysaccharides or polypeptides or its respective derivatives, obtainable by free radical polymerization of a) a monomer selected from or a monomer mixture of (a) from 20 to 100% by weight of acrylic acid or methacrylic acid or of a mixture thereof or of the alkali metal, alkaline earth metal or ammonium salts thereof, (b) from 0 to 80% by weight of other monoethylenically unsaturated monomers which are copolymerizable with the monomers (a) and (c) from 0 to 5% by weight of monomers having at least 2 ethylenically unsaturated, nonconjugated double bonds in the molecule, in the presence of either b1) polysaccharides, oxidatively, hydrolytically or enzymatically degraded polysaccharides, oxidized hydrolytically degraded or oxidized enzymatically degraded polysaccharides, or such chemically modified degraded products, chemically modified mono-, oligo-or poly-saccharides or mixtures of the stated compounds and/or b2) polypeptides, their hydrolysates or enzymaticallydegraded and optionally chemically modified products or mixtures of the stated compounds in a weight ratio a: (b1 or b2) of from 1:99 to 18:82 or in a weight ratio a:(b1+b2) of from 60:40 to 1:99 and b1:b2 of from 97:3 to 3:97 used as tanning agents.. .
|Molecular markers of plant embryogenesis|
The present invention relates generally to a molecular marker for a plant physiological process and more particularly for plant embryogenesis. The molecular marker is, in one form, a genetic sequence from a monocot plant such as but not limited to oil-palm plants.
|Plants having enhanced yield-related traits and a method for making the same|
The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a yield enhancing protein (yep).
|Peptide conjugates and fluorescence detection methods for intracellular caspase assay|
Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence.
|Inhibitors of type 2 vascular endothelial growth factor receptors|
The present disclosure relates to novel vascular endothelial growth factor receptor (vegfr)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (vegfs). The present disclosure also provides various improvements relating to single domain binding polypeptides..
|Methods and compositions reducing target gene expression using cocktails of sirnas or constructs expressing sirnas|
The present invention concerns methods and compositions involving the production or generation of sirna mixtures or pools capable of triggering rna-mediated interference (rnai) in a cell. Compositions of the invention include kits that include reagents for producing or generating sirna pools.
|Methods and compounds to inhibit enveloped virus release|
A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex.
|Polypeptide, nucleotide sequence thereof, and method for using the same for preventing dna synthesis and inhibiting cell proliferation|
A polypeptide represented by seq. Id.no.
|Natriuretic polypeptide delivery systems|
This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided..
|Fgf-9 and its use relating to blood vessels|
There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a fgf-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated fgf-9 polypeptide and one or more other angiogenic polypeptides.
|Apolipoprotein e polypeptides and their use|
Disclosed herein are several apoplipoprotein e (apoe) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis c virus infection. These apoe polypeptides can inhibit the entry of hepatitis c virus into cells, and inhibit viral replication.
|Polypeptides having cellulase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having cellulase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Method for detecting pancreatic cancer|
This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against caprin-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a caprin-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same..
|Immunoglobulin fc libraries|
Methods and composition for the screening and isolation of aglycosylated antibody fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated fc domains that bind to fc receptors or preferentially bind to particular fc receptors are described.
|Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules|
The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like.